AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.
Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group
VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.
Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech
Agreement sets basis for new areas of therapy
At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”
Development in cooperation with Leukos
As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.
About Leukos
Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.
About the Josep Carreras Foundation
The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.
About the Josep Carreras Leukaemia Research Institute
The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus
About Inveready
Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).
Mag Nina Roth, MAS
nina.roth@aop-health.com
AOP Health
Needs. Science. Trust.
AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group
Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/
https://www.globenewswire.com/